Cell Therapy Manufacturing Market (By Therapy Type: Allogenic Cell Therapy, Autologous Cell Therapy; By Technology Type: Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, 3D Technology; By Source: IPSC, Bone Marrow, Umbilical Cord, Adipose Tissues, Neural Stem; By Application) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global cell therapy manufacturing market size was valued at USD 4.20 billion in 2023 and is anticipated to reach around USD 16.89 billion by 2033, growing at a CAGR of 14.93% from 2024 to 2033. The rising incidence of chronic diseases such as cancer, autoimmune disorders, and degenerative conditions are key factors driving the market growth.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. cell therapy manufacturing market size was estimated at USD 1.29 billion in 2023 and is predicted to be worth around USD 5.24 billion by 2033, at a CAGR of 15.04% from 2024 to 2033.
North America dominated the global cell therapy manufacturing market. The United States led in North America in 2023 and is expected to maintain this position in the forecast period. Factors such as the rising prevalence of sickle cell disease and the presence of numerous developers of gene, cell, and tissue-based therapeutics are driving growth. Moreover, the region benefits from many contract development organizations and local companies are expanding their manufacturing facilities.
Asia Pacific is expected to witness the fastest growth during the forecast period. Countries such as China, Japan, and South Korea are investing heavily in research and development and constructing state-of-the-art manufacturing facilities. The region benefits from a sizable patient population, rising healthcare spending, and government support to foster the growth and acceptance of cell therapies. Additionally, Asia Pacific is becoming a center for contract manufacturing organizations (CMOs) providing cell therapy manufacturing services.
The Asia Pacific cell therapy manufacturing market size was calculated at USD 970 million in 2023 and is projected to expand around USD 3,970 million by 2033, poised to grow at a CAGR of 15.13% from 2024 to 2033.
Year | Market Size (USD Million) |
2023 | 970 |
2024 | 1,110 |
2025 | 1,280 |
2026 | 1,470 |
2027 | 1,690 |
2028 | 1,940 |
2029 | 2,230 |
2030 | 2,560 |
2031 | 2,940 |
2032 | 3,380 |
2033 | 3,970 |
The cell therapy manufacturing market comprises industries that produce therapeutic products using isolated tissue to treat disorders or wounds. Cell therapy manufacturing is essential for developing and commercializing cell-based treatments, such as CAR-T cell and stem cell therapies. It is critical to have efficient and scalable manufacturing processes to meet the increasing demand for these innovative treatments and make them available to patients around the world.
The process of cell therapy includes harvesting cells from a patient or donor, modifying or growing them in a lab, and then reintroducing them into the patient's body to improve biological functions. Manufacturing includes steps like isolating cells, expanding them, performing genetic modifications if needed, conducting quality control tests, and preparing the final product. These steps are carried out in highly controlled environments to ensure the safety, purity, and effectiveness of therapeutic cells.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 14.93% |
Cell Therapy Manufacturing Market Size in 2023 | USD 4.20 Billion |
Cell Therapy Manufacturing Market Size in 2024 | USD 4.83 Billion |
Cell Therapy Manufacturing Market Size by 2033 | USD 16.89 Billion |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Therapy Type, By Technology Type, By Source, and By Application |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver: Outsourcing manufacturing processes
In the cell therapy manufacturing market, businesses not well-versed in cell therapy manufacturing, establishing a robust supply chain to meet consumer demand can be daunting and time-consuming. Companies with a strong grasp of their product's biology but lack experience in transitioning from small-scale to large-scale automated production can bridge this gap with the help of external organizations like contract manufacturing organizations (CMOs).
Outsourcing manufacturing capabilities presents growth opportunities for new players in the cell therapy manufacturing market to scale up their products for widespread distribution. Moreover, it spares manufacturers from investing in extensive systems and helps them prepare for potential product delays or regulatory challenges in the future.
Restraint: Complex manufacturing process
The cell therapy manufacturing market is complex due to biological variations, making it difficult to standardize and ensure quality control. Moving from small-scale research to large-scale production while maintaining consistent product quality is a major hurdle. Additionally, meeting strict regulatory standards, especially for new and personalized therapies, adds further challenges, particularly concerning product safety, effectiveness, and manufacturing protocols.
Opportunity: Increasing use of allogeneic therapies
Allogeneic cell therapies offer advantages as they produce immune cells that can target and eliminate cancer cells left behind by chemotherapy. These therapies come from healthy sources, providing a greater supply of functional cells. Moreover, allogeneic techniques allow for the creation of multiple medicines, making them a key driver of growth in the cell therapy manufacturing market. Compared to autologous therapies, allogeneic treatments are notably more cost-effective, further fueling the expansion of the market.
Despite the limited number of approvals, companies specializing in cell therapies are attracting increased funding from both private investors and government sources. Over the projected period, there has been a significant rise in private equity and capital investments in the life sciences sector. As a result, investments in the cell therapy industry play a crucial role in driving the growth of the cell therapy manufacturing market.
The autologous cell therapy segment was the leading therapy type in the cell therapy manufacturing market in 2023. Autologous therapy is a novel treatment approach that involves using a person's own cells or tissues. These cells or tissues are treated outside the body before being re-inserted into the donor. This method is widely used in various fields of medicine, including orthopedics and dermatology, for both therapeutic and cosmetic purposes.
According to market projections, the allogenic cell therapy segment is expected to experience the highest growth rate in the cell therapy manufacturing market over the forecast period. Allogenic cell therapies involve using cells from healthy donors of the same species, as opposed to xenogeneic therapies, which use cells from different species. In this type of therapy, cells are expanded and potentially modified to treat multiple patients.
The somatic cell technology segment held the largest share of the cell therapy manufacturing market in 2023. These benefits stem from this type of therapy. Besides advancing stem cell research and therapies, somatic cell nuclear transfer (SCNT) has the special ability to produce cells tailored to individual patients for regenerative medicine. Also, it can be used to breed transgenic animals for biomedical purposes. These factors can drive the segment growth further.
The 3D technology segment is expected to grow at the fastest rate during the projected period. This is attributed to the three-dimensional (3D) technologies, like biomaterial scaffolds, that serve various purposes. They support cell survival, prompt cell specialization, provide a surface for cell growth, aid tissue regeneration, determine tissue shape and size, deliver growth factors, and shield cell transplants from the immune system to prevent rejection. These are some important functions of 3D technologies in medical applications.
The IPSC (induced pluripotent stem cell) segment dominated the cell therapy manufacturing market in 2023. Induced pluripotent stem cells (iPSCs) are viewed as an excellent option for creating ready-made allogeneic cell therapies. They can multiply indefinitely, are easily modified genetically, allow for the selection of specific clones after modification, and eliminate the need for individual cell collection.
The bone marrow segment is the second largest segment in the global cell therapy manufacturing market. A bone marrow transplant (BMT) is a specialized treatment for individuals with specific cancers or other medical conditions. It entails extracting stem cells from the bone marrow, filtering them, and reintroducing them into either the same individual (donor) or another recipient.
The oncology segment dominated the cell therapy manufacturing market in 2023. An oncologist is a doctor who specializes in identifying, diagnosing, and treating cancer in patients. They are trained to address various types of cancer affecting different parts of the body. The advancement of biotechnology, personalized medicine, and innovative treatment methods has elevated oncology's significance in the market.
The neurological segment is projected to show the fastest growth during the forecast period. This is because, in recent years, there has been an increasing focus on using cell transplantation or cell therapy to treat nerve injuries. This approach has gained attention for its potential in treating neurological diseases by giving new treatment options. Cell therapy in neurological diseases aims to mimic the natural process of cell repair and development in the nervous system. This can help address the root causes of the disease, improve dysfunction, and facilitate tissue repair.
Segments Covered in the Report
By Therapy Type
By Technology Type
By Source
By Application
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cell Therapy Manufacturing Market
5.1. COVID-19 Landscape: Cell Therapy Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cell Therapy Manufacturing Market, By Therapy Type
8.1. Cell Therapy Manufacturing Market, by Therapy Type, 2024-2033
8.1.1. Allogenic Cell Therapy
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Autologous Cell Therapy
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Cell Therapy Manufacturing Market, By Technology Type
9.1. Cell Therapy Manufacturing Market, by Technology Type, 2024-2033
9.1.1. Somatic Cell Technology
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Cell Immortalization Technology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Viral Vector Technology
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Genome Editing Technology
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Cell Plasticity Technology
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. 3D Technology
9.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Cell Therapy Manufacturing Market, By Source
10.1. Cell Therapy Manufacturing Market, by Source, 2024-2033
10.1.1. IPSC (Induced Pluripotent Stem Cell)
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Bone Marrow
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Umbilical Cord
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Adipose Tissues
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Neural Stem
10.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Cell Therapy Manufacturing Market, By Application
11.1. Cell Therapy Manufacturing Market, by Application, 2024-2033
11.1.1. Musculoskeletal
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Gastrointestinal
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Neurological
11.1.4.1. Market Revenue and Forecast (2021-2033)
11.1.5. Oncology
11.1.5.1. Market Revenue and Forecast (2021-2033)
11.1.6. Dermatology
11.1.6.1. Market Revenue and Forecast (2021-2033)
11.1.7. Others
11.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Cell Therapy Manufacturing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.3. Market Revenue and Forecast, by Source (2021-2033)
12.1.4. Market Revenue and Forecast, by Application (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.1.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.1.6.4. Market Revenue and Forecast, by Application (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.4. Market Revenue and Forecast, by Application (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.6.4. Market Revenue and Forecast, by Application (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.7.4. Market Revenue and Forecast, by Application (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.8.4. Market Revenue and Forecast, by Application (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.4. Market Revenue and Forecast, by Application (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.6.4. Market Revenue and Forecast, by Application (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.7.4. Market Revenue and Forecast, by Application (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.8.4. Market Revenue and Forecast, by Application (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.4. Market Revenue and Forecast, by Application (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.6.4. Market Revenue and Forecast, by Application (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.7.4. Market Revenue and Forecast, by Application (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.8.4. Market Revenue and Forecast, by Application (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.5.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.5.6.4. Market Revenue and Forecast, by Application (2021-2033)
Chapter 13. Company Profiles
13.1. Abbott
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent, Inc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bio-Techne
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Cytiva
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Lonza
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. The Discovery Labs
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bristol-Myers Squibb Company
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Gilead Sciences, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client